2025 net revenues increased 5.7% to $1.164 billion , compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 2024 2025 Adjusted EBITDA (1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis 2025 Adjusted EPS (1) of $0.86, an increase of $0.16 per diluted share, compared to 2024 Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2025 and its initial 2026 outlook. Fourth-quarter 2025 net revenues increased 4.6% to $303 million, compared to $290 million in the fourth-quarter 2024.
